AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23648611 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo group)
Number of subjects: 46
Study 23648611 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 46
Study 20727237 — intervention group
Group type: COMPARATOR
Intervention: Fibre supplement (psyllium)
Number of subjects: 100
Study 20727237 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating plus fibre supplement (HLT-FIB)
Number of subjects: 100
Study 20727237 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating (HLT)
Number of subjects: 100
Study 20727237 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (placebo)
Number of subjects: 100
Study 20727237 — intervention group
Group type: COMPARATOR
Intervention: Fibre supplement (FIB)
Number of subjects: 100
Study 20727237 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating plus placebo (HLT)
Number of subjects: 100
Study 19952360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment in men
Number of subjects: 1192
Study 19952360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment in women
Number of subjects: 1192
Study 17161934 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission education using the concept map method with written educational material (Group A)
Number of subjects: 123
Study 17161934 — intervention group
Group type: COMPARATOR
Intervention: Standard preadmission education (written educational material with non-systematic oral education) (Group B)
Number of subjects: 123
Study 14984434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 674
Study 14984434 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 674
Study 11157645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity oral anticoagulant therapy (targeted INR of 2.5; range, 2.0 to 3.0)
Number of subjects: 0
Study 11157645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity regimens (INR < 2.0)
Number of subjects: 0
Study 11157645 — intervention group
Group type: EXPERIMENTAL
Intervention: IV heparin
Number of subjects: 0
Study 11157645 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin dosage and age (> 70 years)
Number of subjects: 0
Study 11157645 — intervention group
Group type: COMPARATOR
Intervention: LMW heparin
Number of subjects: 0
Study 11157645 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 0
Study 9644644 — intervention group
Group type: EXPERIMENTAL
Intervention: Indium scans and removal of clotted grafts in patients with fever or sepsis
Number of subjects: 20
Study 9644644 — intervention group
Group type: COMPARATOR
Intervention: Indium scans and removal of clotted grafts in asymptomatic control subjects
Number of subjects: 20
Study 9644644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial cultures of recovered surgical material and blood
Number of subjects: 20
Study 9644644 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart review of past infectious episodes
Number of subjects: 20
Study 8181318 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure ventilatory support system (BiPAP)
Number of subjects: 22
Study 8181318 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 22
Study 3371392 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release metoprolol, 100 mg once daily
Number of subjects: 27
Study 3371392 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoprolol tablets, 100 mg once daily
Number of subjects: 27
Study 31200629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic scapular recognition exercise using a wireless biofeedback system
Number of subjects: 66
Study 31200629 — intervention group
Group type: COMPARATOR
Intervention: Active range-of-motion (ROM) exercises of the sound upper limb (Control)
Number of subjects: 66
Study 30127136 — intervention group
Group type: EXPERIMENTAL
Intervention: ARK-30 autorefractor without cycloplegia
Number of subjects: 30
Study 30127136 — intervention group
Group type: EXPERIMENTAL
Intervention: ARK-30 autorefractor under cycloplegia
Number of subjects: 30
Study 30127136 — intervention group
Group type: COMPARATOR
Intervention: Retinoscopy
Number of subjects: 30
Study 27335139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (n = 26)
Number of subjects: 75
Study 27335139 — intervention group
Group type: COMPARATOR
Intervention: Lactating women (n = 28)
Number of subjects: 75
Study 27335139 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (n = 75)
Number of subjects: 75
Study 27335139 — intervention group
Group type: COMPARATOR
Intervention: Control women (n = 21)
Number of subjects: 75
Study 24709242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 126
Study 24709242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 22033512 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe-heavy (S-H)
Number of subjects: 7
Study 22033512 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe-moderate (S-M)
Number of subjects: 7
Study 22033512 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe-light (S-L)
Number of subjects: 7
Study 22033512 — intervention group
Group type: COMPARATOR
Intervention: Severe-intensity constant-work-rate (S-CWR)
Number of subjects: 7
Study 20507557 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand relaparotomy strategy
Number of subjects: 229
Study 20507557 — intervention group
Group type: COMPARATOR
Intervention: Planned relaparotomy strategy
Number of subjects: 229
Study 18257187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation
Number of subjects: 26
Study 18257187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no catgut implanted)
Number of subjects: 26
Study 16200558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-to-low payment card format
Number of subjects: 314
Study 16200558 — intervention group
Group type: COMPARATOR
Intervention: Low-to-high payment card format
Number of subjects: 314
Study 16200558 — intervention group
Group type: COMPARATOR
Intervention: Randomly shuffled payment card format
Number of subjects: 314
Study 16200558 — intervention group
Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 314
Study 16200558 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 314
Study 12920415 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical antipsychotic discontinuation (n = 12)
Number of subjects: 24
Study 12920415 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotic continuation (n = 12)
Number of subjects: 24
Study 10902990 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supplement (E) = 1171 kJoule + 12 mg iron
Number of subjects: 136
Study 10902990 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (M) = 12 mg iron + 209 kJ
Number of subjects: 136
Study 10902990 — intervention group
Group type: COMPARATOR
Intervention: Supplement (S) = 104 kJ
Number of subjects: 136
Study 9371853 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 900
Study 9371853 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study 1590284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine sulfate (SRMS) tablets, 30 mg every 12 hours
Number of subjects: 27
Study 1590284 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) solution, same mg/24 hours dose, every 4 hours
Number of subjects: 27
Study 1590284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine sulfate (SRMS) tablets
Number of subjects: 27
Study 1590284 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) solution
Number of subjects: 27
Study 4003636 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills intervention to prevent cigarette smoking
Number of subjects: 689
Study 4003636 — intervention group
Group type: COMPARATOR
Intervention: Health information alone
Number of subjects: 689
Study 4003636 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 689
Study 29733008 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct imprint glove-sampling methodology
Number of subjects: 0
Study 29733008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sponge stick glove-sampling methodology
Number of subjects: 0
Study 26706667 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-tailored contingency management intervention for alcohol abstinence
Number of subjects: 400
Study 26706667 — intervention group
Group type: COMPARATOR
Intervention: Control condition (receiving reinforcers for attending study visits regardless of alcohol use)
Number of subjects: 400
Study 24853275 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TACE
Number of subjects: 35
Study 24853275 — intervention group
Group type: COMPARATOR
Intervention: Control (non-TACE)
Number of subjects: 35
Study 22458978 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning program (n = 16)
Number of subjects: 30
Study 22458978 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 30
Study 20457286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Number of subjects: 40
Study 20457286 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol
Number of subjects: 40
Study 17681999 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 401
Study 17681999 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-resolution imaging
Number of subjects: 401
Study 15755234 — intervention group
Group type: EXPERIMENTAL
Intervention: Full IMB session
Number of subjects: 625
Study 15755234 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counseling
Number of subjects: 625
Study 12721256 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Intensification (DI) phase of therapy for 7 weeks
Number of subjects: 778
Study 12721256 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen without Delayed Intensification
Number of subjects: 778
Study 12721256 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for eligible patients
Number of subjects: 778
Study 12721256 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Intensification (DI) phase of therapy
Number of subjects: 778
Study 10474123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile GnRH infusion (100 ng/kg i.v. every 90 min for 2 weeks)
Number of subjects: 10
Study 10474123 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 10
Study 8709374 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection plus mitomycin C (20 mg/50 ml sodium chloride, every 2 weeks during year 1 and once a month during year 2)
Number of subjects: 337
Study 8709374 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection plus bacillus Calmette-Guerin (BCG) (120 mg/50 ml sodium chloride, instilled once a week for 6 weeks and once a month for 4 months)
Number of subjects: 337
Study 8709374 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection only
Number of subjects: 337
Study 8709374 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapy groups (mitomycin C, BCG, and transurethral resection only)
Number of subjects: 337
Study 1855607 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of intrapartum ampicillin intravenously
Number of subjects: 121
Study 1855607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 6881978 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy using Nocardia rubra cell wall skeleton
Number of subjects: 41
Study 6881978 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 41
Study 6881978 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III and P.S. 0+1+2 patients
Number of subjects: 41
Study 30794953 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol with HMG and low dose (100IU/day) hCG
Number of subjects: 240
Study 30794953 — intervention group
Group type: EXPERIMENTAL
Intervention: Short GnRH-agonist protocol with HMG and low dose (100IU/day) hCG
Number of subjects: 240
Study 28462571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance running and strength training program once a week (ES30)
Number of subjects: 41
Study 28462571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance running and strength training program twice a week (ES60)
Number of subjects: 41
Study 28462571 — intervention group
Group type: COMPARATOR
Intervention: Endurance running (E)
Number of subjects: 41
Study 27082736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of anti-VEGF drugs (ranibizumab and/or aflibercept)
Number of subjects: 45
Study 27082736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative number of aflibercept injections
Number of subjects: 45
Study 27082736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative number of intravitreal injections of overall anti-VEGF drugs
Number of subjects: 45
Study 24902075 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 60
Study 24902075 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 60
Study 22021122 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrahyoid flap reconstruction
Number of subjects: 18
Study 22021122 — intervention group
Group type: COMPARATOR
Intervention: Free radial forearm flap reconstruction
Number of subjects: 18
Study 19786130 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-423557 (daily oral administration)
Number of subjects: 2
Study 19786130 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-423562 (single intravenous dose)
Number of subjects: 2
Study 19786130 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-423557 (single oral dose)
Number of subjects: 2
Study 19786130 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-423557 (higher doses)
Number of subjects: 2
Study 19786130 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study 17479288 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.0 mg/m(2)/day 168‐h continuous infusion), cyclophosphamide (100 mg/m(2)/day 1‐h infusion days 1‐7), etoposide (100 mg/m(2)/day 1‐h infusion days 8‐10)
Number of subjects: 42
Study 17479288 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan, cyclophosphamide, and etoposide
Number of subjects: 42
Study 15209391 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal washing with povidone iodine and insertion of chloramphenicol vaginal tablets in women with IL-8 elevations (Group B)
Number of subjects: 0
Study 15209391 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (Group A, no treatment)
Number of subjects: 0
Study 15209391 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (Group C, treatment not specified)
Number of subjects: 0
Study 11668157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia
Number of subjects: 6163
Study 9830832 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine (GLN) 0.03 g.kg body mass‐1
Number of subjects: 10
Study 9830832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10
Study 9830832 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine (GLN)
Number of subjects: 10
Study 8089357 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA
Number of subjects: 10
Study 8089357 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine
Number of subjects: 10
Study 8089357 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer control
Number of subjects: 10
Study 2724486 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (3.4 g three times per day for 8 weeks)
Number of subjects: 75
Study 2724486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-length z-scores (WLZ) at 6 months
Number of subjects: 2723
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Length-for-age z-scores (LAZ) at 6 months
Number of subjects: 2723
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-age z-scores (WAZ) at 6 months
Number of subjects: 2723
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of presumed malaria from 6 to 18 months
Number of subjects: 2723
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of clinical malaria from 6 to 18 months
Number of subjects: 2723
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of RDT-confirmed malaria from 6 to 18 months
Number of subjects: 2723
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of malaria parasitaemia at 6 months
Number of subjects: 2723
Study 31010435 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of malaria parasitaemia at 18 months
Number of subjects: 2723
Study 28113069 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate catheter removal
Number of subjects: 31
Study 25311913 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (DF)
Number of subjects: 5
Study 25311913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamonomethoxine (SMM)
Number of subjects: 5
Study 25311913 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of DF and SMM
Number of subjects: 5
Study 24035203 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA (Neurally Adjusted Ventilatory Assist)
Number of subjects: 13
Study 24035203 — intervention group
Group type: COMPARATOR
Intervention: PSV (Pressure Support Ventilation)
Number of subjects: 13
Study 24035203 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 13
Study 21627974 — intervention group
Group type: EXPERIMENTAL
Intervention: Head‐Down Bed Rest (HDBR)
Number of subjects: 22
Study 21627974 — intervention group
Group type: COMPARATOR
Intervention: Sitting Control
Number of subjects: 22
Study 19333672 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric resistance exercise rehabilitation program
Number of subjects: 17
Study 19333672 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance exercise rehabilitation program
Number of subjects: 17
Study 15883229 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg and placebo
Number of subjects: 50
Study 15883229 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg and ramipril 10 mg
Number of subjects: 50
Study 15883229 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg and placebo
Number of subjects: 50
Study 15883229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (simvastatin 20 mg and ramipril 10 mg)
Number of subjects: 50
Study 10333380 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depression
Number of subjects: 34
Study 10333380 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 34
Study 7486293 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapleural analgesia with 20 mL of 0.5% bupivacaine
Number of subjects: 20
Study 7486293 — intervention group
Group type: COMPARATOR
Intervention: Intrpleural analgesia with 20 mL of 0.5% bupivacaine
Number of subjects: 20
Study 7486293 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapleural analgesia
Number of subjects: 20
Study 7486293 — intervention group
Group type: COMPARATOR
Intervention: Intrpleural analgesia
Number of subjects: 20
Study 1663914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (800 mg)
Number of subjects: 16
Study 1663914 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg)
Number of subjects: 16
Study 1663914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6958473 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer devices with budesonide (low and high dosages)
Number of subjects: 0
Study 6958473 — intervention group
Group type: COMPARATOR
Intervention: Inhaled terbutaline pretreatment
Number of subjects: 0
Study 31658544 — intervention group
Group type: EXPERIMENTAL
Intervention: GDFM
Number of subjects: 30
Study 31658544 — intervention group
Group type: COMPARATOR
Intervention: Conventional liquid management
Number of subjects: 30
Study 29705115 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction mask
Number of subjects: 45
Study 29705115 — intervention group
Group type: COMPARATOR
Intervention: Conventional mask
Number of subjects: 45
Study 27207905 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8mg/d
Number of subjects: 0
Study 27207905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27207905 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 0, 4, 8, or 16mg/d
Number of subjects: 0
Study 23990446 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted THA
Number of subjects: 100
Study 23990446 — intervention group
Group type: COMPARATOR
Intervention: Conventional THA
Number of subjects: 100
Study 22901830 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 118
Study 22901830 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 118
Study 22901830 — intervention group
Group type: COMPARATOR
Intervention: Gout patients
Number of subjects: 118
Study 21057509 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous attention with small stimuli and spatial uncertainty
Number of subjects: 0
Study 21057509 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous attention with large stimuli at one location (no uncertainty)
Number of subjects: 0
Study 21057509 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging experiment with wider attention fields
Number of subjects: 0
Study 17653005 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert nitinol stents
Number of subjects: 47
Study 15785303 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4 IU every other day for 3 months
Number of subjects: 12
Study 11989050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 60 mg i.v. 30 min before ESWL
Number of subjects: 60